Seminars in Oncology
Volume 30, Issue 3 , Pages 338-348 , June 2003

The follow-up of breast cancer

  • Leisha A. Emens

      Affiliations

    • Department of Oncology, The Johns Hopkins University, Baltimore, MD, USA
    • ,
  • Nancy E. Davidson

      Affiliations

    • Department of Oncology, The Johns Hopkins University, Baltimore, MD, USA
    • *Address reprint requests to Nancy E. Davidson, MD, Sidney Kimmel Comprehensive Cancer Center, Bunting Blaustein Cancer Research Building, 1650 Orleans St, Room 409, Baltimore, MD 21231-1000 USA

References 

  1. American Cancer Society . Cancer Facts and Figures 2002. Atlanta, GA: American Cancer Society,; 2002;
  2. Howe HL, Wingo PA, Thun MJ, et al.  The Annual Report to the Nation on the Status of Cancer (1973-1998), Featuring Cancers With Recent Increasing Trends. J Natl Cancer Inst. 2001;93:824–842
  3. Garfinkel L, Boring CC, Heath CW. Changing trends: An overview of breast cancer incidence and mortality. Cancer. 1994;74:222–227
  4. Ernster VL, Barclay J, Kerlikowske K, et al.  Incidence and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913–918
  5. Rosen PP, Groshen S, Siago P, et al.  Prognosis in T2N0M0 stage I breast carcinoma: A 20-year follow-up study. J Clin Oncol. 1991;9:1650–1661
  6. Rosen PP, Groshen S, Kinne DW, et al.  Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long term follow up. J Clin Oncol. 1993;11:2090–2100
  7. Langlands AO, Pocock SJ, Kerr GR. Long-term survival of patients with breast cancer: A study of the curability of the disease. Br Med J. 1979;286:1777–1779
  8. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–2746
  9. Carter CL, Allen C, Hensen DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–187
  10. Bijker N, Petersen JL, Duchateau L, et al.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer trial 10853. J Clin Oncol. 2001;19:2263–2271
  11. Haagensen CD, Lane N, Lattes R. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737–769
  12. Rosen PP, Lieberman P, Braune D. Lobular carcinoma in situ of the breast: Detailed analysis of 99 patients with an average follow up of 24 years. Am J Surg Pathol. 1978;2:225–251
  13. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978;41:1170–1177
  14. Ries LA, Hensen DE, Harras A. Survival from breast cancer according to tumor size and nodal status. Surg Oncol Clin North Am. 1994;3:35–52
  15. Kamby C, Vejborj I, Kristensen B. Stage and pattern of metastases in patients with breast cancer. Cancer. 1988;62:2226–2233
  16. Leborgne F, Leborgne J, Ortega B, et al.  Breast conservation treatment of early stage breast cancer: Patterns of failure. Int J Rad Oncol Biophys. 1995;15:765–775
  17. Hannisdal E, Gundersen S, Kvaloy S. Follow-up of breast cancer patients stage I-II: A baseline strategy. Eur J Cancer. 1993;29:992–997
  18. Tomin R, Donegan W. Screening for recurrent breast cancer: Its effectiveness and prognostic value. J Clin Oncol. 1987;5:62–67
  19. Zwaveling A, Albers GH, Felthuis W, et al.  An evaluation of routine follow up for detection of breast cancer recurrences. J Surg Oncol. 1987;34:194–197
  20. Rutgers EJ, van Sluten EA, Kluck HM. Follow-up after primary treatment of primary breast cancer. Br J Surg. 1989;76:187–190
  21. Pandya KJ, McFadden E, Kalish LA, et al.  Frequency and patterns of early disease recurrence and method of detection in operable breast cancer with pathologically positive axillary lymph nodes on Eastern Cooperative Oncology Group adjuvant studies: A preliminary report. Cancer Treat Symp. 1983;2:117–122
  22. Pedrazzini A, Gelber R, Isley M, et al.  First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol. 1986;4:389–394
  23. Broyn T, Froyen J. Evaluation of routine follow up after surgery for breast carcinoma. Acta Chir Scand. 1982;148:401–404
  24. Hatschek T, Castensen J, Fagerber G. Influence of S-phase fraction on metastatic pattern and post-recurrence survival in a randomized mammography screening trial. Breast Cancer Res Treat. 1989;14:321–327
  25. Strier M, Rosen H. Influence of early diagnosis on prognosis of early breast cancer. Cancer. 1989;64:1128–1131
  26. Valagussa P, Tess T, Rossi A, et al.  Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes. Breast Cancer Res Treat. 1981;1:349–359
  27. Recht A, Schnitt SJ, Connolly JL. Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma. Int J Radiat Oncol Biol Phys. 1989;16:3–9
  28. Fowble B, Solin L, Shultz DJ. Breast recurrence following conservative surgery and radiation: Patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys. 1990;19:833–842
  29. Moore M, Kinne D. Patient selection criteria for conservation surgery versus mastectomy: Memorial Hospital experience. World J Surg. 1994;18:58–62
  30. Veronesi U, Luini A, Del Vecchio M. Radiotherapy after breast conserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328:1587–1591
  31. Rosenman J, Bernard S, Kober C. Local recurrences in patients with breast cancer at the North Carolina Memorial Hospital (1970-1982). Cancer. 1986;57:1421–1425
  32. Ahearne PM, Leach SD, Feig BW. Invasive Breast Cancer. Philadelphia, PA: Lippincott Williams & Wilkins,; 1998;
  33. Hughes LE, Courtney SP. Follow-up of patients with breast cancer. Brit Med J. 1985;290:1229–1230
  34. Early Breast Cancer Trialists Collaborative Group . Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials. N Engl J Med. 1995;333:1444–1451
  35. Meyer JE, Munzenreider JE. Computed tomographic demonstration of internal mammary lymph-node metastasis in patients with locally recurrent breast carcinoma. Radiology. 1981;139:661
  36. Villari N, Fargnoli R, Mungai R. CT evaluation of chest wall recurrences of breast cancer. Eur J Radiol. 1983;5:206–208
  37. Smith TJ, Davidson NE, Schapira DV, et al.  American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999;17:1080–1082
  38. Schapira DV, Urban N. A minimalist policy for breast cancer surveillance. JAMA. 1991;265:380–382
  39. Mellink WA, Holland R, Hendriks JHCL. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer. 1991;67:1844–1848
  40. Crivellari D, Price KN, Hagen M, et al.  Routine tests during follow-up of patients after primary treatment for operable breast cancer. Ann Oncol. 1995;6:769–776
  41. Bast RC, Ravdin P, Hayes DF, et al.  2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–1878
  42. Molina R, Zanon G, Vilella X, et al.  Use of serial carcinoembryonic antigen and CA15-3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36:41–48
  43. Jager W, Kramer S, Palapelas V, et al.  Breast cancer and clinical utility of CA15-3 and CEA. Scand J Clin Lab Invest. 1995;221:87–92
  44. Chan DW, Beveridge RA, Muss H, et al.  Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and III disease. J Clin Oncol. 1997;15:2322–2328
  45. Safi F, Kohler I, Rottinger E, et al.  The value of the tumor marker CA15-3 in diagnosing and monitoring breast cancer. Cancer. 1991;68:574–582
  46. Kokko R, Holli K, Hakama M. CA15-3 in the follow up of localized breast cancer: A prospective study. Eur J Cancer. 2002;38:1189–1193
  47. Gion M, Mione R, Leon AE, et al.  Comparison of the diagnostic accuracy of CA27-29 and CA15-3 in primary breast cancer. Clin Chem. 1999;45:630–637
  48. Wickerham L, Fisher B, Cronin W, et al.  The efficacy of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Res Treat. 1984;4:303–307
  49. Chaudary MM, Maisey MN, Shaw PJ. Sequential bone scans and chest radiographs in the postoperative management of early breast cancer. Br J Surg. 1983;70:517–520
  50. Roselli del Turco M, Palli D, Cariddi A, et al.  Intensive diagnostic follow-up after treatment of primary breast cancer—A randomized trial: National Research Council Project on Breast Cancer Follow-Up. JAMA. 1994;271:1587–1592
  51. GIVIO Investigators . Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA. 1994;271:1587–1592
  52. Kauczor HU, Voges EM, Wieland-Schneider C, et al.  Value of routine abdominal and lymph node sonography in the follow-up of breast cancer patients. Eur J Radiol. 1994;18:104–108
  53. Wahl RL. Current Status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol. 2001;36:250–260
  54. Eubank WB, Mankoff DA, Vesselle HJ, et al.  Detection of locoregional and distant recurrences in breast cancer patients using FDG-PET. Radiographics. 2002;22:5–17
  55. Hathaway PB, Mankoff DA, Maravilla KR, et al.  Value of combined FDG-PET and MR imaging in the evaluation of suspected local-regional breast cancer: Preliminary experience. Radiology. 1999;210:807–814
  56. Cook GJ, Houston S, Rubens R, et al.  Detection of bone metastases in breast cancer by 18F-FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–3379
  57. Rojas MP, Telaro E, Russo A, et al.  Follow-Up Strategies for Women Treated for Early Breast Cancer. (Cochrane Review) Oxford, UK: Update Software,; 2002;
  58. Stearns V, Hayes DF. Approach to menopausal symptoms in women with breast cancer. Curr Treat Options Oncol. 2002;3:179–190
  59. Fisher B, Constantino CJ, Wickerham DL. Tamoxifen for prevention of breast cancer: Report of the National Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1988;90:1371–1388
  60. Barakat RR, Gilewski T, Almadrones L, et al.  Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy. J Clin Oncol. 2000;18:3459–3463
  61. Gerber B, Krause A, Muller H, et al.  Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000;18:3464–3470
  62. Grunfeld E, Mant D, Yudkin P, et al.  Routine follow up of breast cancer in primary care: Randomized trial. Br Med J. 1996;313:665–669
  63. Grunfeld E, Mant D, Yudkin P, et al.  Follow-up of breast cancer in primary care vs specialist care: Results of an economic evaluation. Br J Cancer. 1999;79:1227–1233
  64. Gulliford T, Opomo M, Wilson E, et al.  Popularity of less frequent follow-up for breast cancer in randomized study: Initial findings from the Hotline Study. Br Med J. 1997;314:171–177
  65. Carlson RW, Anderson BO, Bensinger W, et al.  NCCN Practice Guidelines for Breast Cancer. Oncology. 2000;14:33–49
  66. Steering Committee on Clinical Practice . Guidelines for the Care and Treatment of Breast Cancer: Follow-up after treatment for breast cancer. Can Med Assoc J. 1998;158:565–583
  67. ISource National Breast Centre . In Follow-up, in Clinical Practice Guidelines for the Management of Early Breast Cancer. In: Woolloomooloo, NSW: NHMRC NBCC,; 2001;p. 97–102

PII: S0093-7754(03)00094-0

Seminars in Oncology
Volume 30, Issue 3 , Pages 338-348 , June 2003

Article Tools